Evidence map›Paper›PMID 39989459›Full record

ArticleJCI insight2025

SPP1hi macrophages, NKG7 T cells, CCL5hi fibroblasts, and IgM plasma cells are dominant features of necrobiosis.

Stephanie T Le, Alina I Marusina, Alexander A Merleev, Amanda Kirane, Olga Kruglinskaya, Andrey Kunitsyn, Nikolay Yu Kuzminykh, Xianying Xing, Sophie Y Li, William Liakos and 11 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Stephanie T LeDepartment of Dermatology, and.
Alina I MarusinaDepartment of Dermatology, and.
Alexander A MerleevDepartment of Dermatology, and.
Amanda KiraneDepartment of Surgery, University of California, Davis, Sacramento, California, USA.
Olga KruglinskayaPhysioseq, Sacramento, California, USA.
Andrey KunitsynPhysioseq, Sacramento, California, USA.
Nikolay Yu KuzminykhInstitute of Biochemical Physics, Russian Academy of Science, Moscow, Russia.
Xianying XingDepartment of Dermatology.
Sophie Y LiPhysioseq, Sacramento, California, USA.
William LiakosDepartment of Dermatology, and.
J Michelle KahlenbergDepartment of Dermatology.
Andrea GompersDepartment of Dermatology, and.
Lauren DowningDepartment of Dermatology, and.
Sahiti MarellaDepartment of Dermatology.
Allison C BilliDepartment of Dermatology.
Paul W HarmsDepartment of Dermatology.
Lam C TsoiDepartment of Dermatology.
Marie-Charlotte BrüggenDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Iannis E AdamopoulosDivision of Rheumatology and Clinical Immunology, Beth Israel Medical Deaconess Center, Boston, Massachusetts, USA.
Johann E GudjonssonDepartment of Dermatology.
Emanual MaverakisDepartment of Dermatology, and.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
University of Michigan Skin Biology and Diseases Resource-based CenterP30AR075043 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDRZEJ A. DLUGOSZ · 2019 to 2026
$6.6M
TRAINING PROGRAM IN CELL AND MOLECULAR DERMATOLOGYT32AR007197 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JAMES TILFORD ELDER, Sunny Y Wong · 1986 to 2026
$4.2M
Mentoring Translational Scientists in Clinical Trial Immune MonitoringK24AR077313 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MAVERAKIS, EMANUAL M. · 2021 to 2025
$939k
Mechanisms of sex discrepancy in autoimmune disease: Regulation of the female-biased VGLL3 immune pathwayK08AR078251 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BILLI, ALLISON CHELSA · 2021 to 2025
$865k
Stratedigm S100EON high-parameter flow cytometer to support multi-institutional research programsS10OD032406 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MAVERAKIS, EMANUAL M. · 2022 to 2022
$600k
NCI NIH HHS P30 CA093373NIAMS NIH HHS K08 AR078251NIAMS NIH HHS K24 AR077313NIAMS NIH HHS P30 AR075043NIAMS NIH HHS T32 AR007197NIH HHS S10 OD032406
6 · The paper itself

Abstract

Necrobiosis is a histologic term used to describe abnormal deposits of "degenerating" collagen within the skin. It can be found as an incidental finding in various granulomatous conditions, but is a hallmark of necrobiosis lipoidica (NL) and necrobiotic xanthogranuloma (NXG). There is limited prior research on necrobiosis. Here, we employed single-cell analysis of lesional and nonlesional skin to study the pathophysiology of necrobiosis. Our findings demonstrate that necrobiotic lesional skin is characterized by SPP1hi macrophages expressing MARCO; NKG7-expressing effector CD8+ T cells coexpressing CCL5, IFNG, GZMs, and PRF1; CCL5hi fibroblasts coexpressing CXCL9, diverse collagens (e.g., COL4A4, COL11A1, COL8A1), and TIMP1; and IGHM-expressing plasma cells. Integrative analysis of signaling ligands and receptor expression identified strong cell-cell communication between NKG7+ T cells, CCL5hi fibroblasts, and SPP1-expressing macrophages. In contrast, these cell populations were not dominant features of systemic sclerosis, another collagen deposition disease. Furthermore, although SPP1-expressing macrophages were detectable in sarcoidosis, IFNG-expressing T cells were a more defining feature of sarcoidosis compared with NL and NXG. From these findings, we speculate that necrobiosis results from the deposition of diverse collagens and ECM proteins through a process driven by CCL5-expressing fibroblasts and SPP1-expressing macrophages.

Indexed as

FibroblastsMacrophagesPlasma CellsCD8-Positive T-LymphocytesChemokine CCL5FemaleHumansMaleMiddle AgedSkinChemokine CCL5Autoimmune diseasesDermatologyFibrosisImmunologySkin

Identifiers

PMID39989459
PMCPMC11949047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.